{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:16:34Z","timestamp":1794712594375,"version":"4.9.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1053\/j.gastro.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T09:08:37Z","timestamp":1732007317000},"page":"1307-1343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":247,"title":["AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis"],"prefix":"10.1053","volume":"167","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley N.","family":"Limketkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Haydek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.10.001_bib1","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.10.001_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/apt.13408","article-title":"Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials","volume":"42","author":"Jairath","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib6","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.7326\/M22-0514","article-title":"A\u00a0framework for the development of living practice guidelines in health care","volume":"175","author":"El Mikati","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib7","series-title":"Clinical practice guidelines we can trust","year":"2011"},{"key":"10.1053\/j.gastro.2024.10.001_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Schunemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.crohns.2013.09.010","article-title":"Comparing disease activity indices in ulcerative colitis","volume":"8","author":"Walsh","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.10.001_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.gastro.2024.10.001_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.10.001_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.10.001_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and\u00a0strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.10.001_bib15","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2024.10.001_bib16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.14309\/ajg.0000000000001907","article-title":"Comorbidity influences the comparative safety of biologic therapy in older adults with inflammatory bowel diseases","volume":"117","author":"Cheng","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1053\/j.gastro.2020.02.032","article-title":"Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases","volume":"158","author":"Kochar","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib20","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.10.001_bib21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib22","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib23","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.cgh.2024.01.003","article-title":"Impact of Treatment response on risk of serious infections in patients with\u00a0Crohn's disease: secondary analysis of the PYRAMID registry","volume":"22","author":"Ahuja","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1053\/j.gastro.2024.10.001_bib25","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2024.10.001_bib26","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis [Erratum appears in N Engl J Med. 2006 May 18;354(20):2200]","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCG.0000000000000319","article-title":"Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis","volume":"49","author":"Jiang","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and\u00a0its post hoc analysis","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.10.001_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib39","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.10.001_bib40","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib41","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib43","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2024.10.001_bib44","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)00910-7","article-title":"The efficacy and safety of guselkumab as maintenance therapy in patients with moderate to severely active ulcerative colitis: REsults from the Phase 3 Quasar Maintenace study","volume":"166","author":"Rubin","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib45","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR Phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(23)04757-1","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study","volume":"164","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib47","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib48","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib49","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.10.001_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib51","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.10.001_bib52","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active\u00a0ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib53","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib54","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib55","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.10.001_bib56","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA Technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib57","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.10.001_bib58","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00384-019-03354-7","article-title":"An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease","volume":"34","author":"Ebada","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"10.1053\/j.gastro.2024.10.001_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292231","article-title":"Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis","volume":"18","author":"Herndon","year":"2023","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.10.001_bib60","first-page":"30","article-title":"An update on anti-TNF biosimilar switching-real-world clinical effectiveness and safety","volume":"7","author":"Meade","year":"2024","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib61","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib62","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib63","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib64","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib65","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izae004","article-title":"Extended induction and prognostic indicators of response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT Trials","author":"D'Haens","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.10.001_bib67","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.cgh.2023.05.001","article-title":"Real-world experience with tofacitinib dose de-escalation in patients with moderate and severe ulcerative colitis","volume":"21","author":"Yu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib69","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cgh.2021.02.032","article-title":"Comparative risk of serious infections with tumor necrosis factor alpha antagonists vs vedolizumab in patients with inflammatory bowel diseases","volume":"20","author":"Singh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib70","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib71","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","article-title":"Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO Registry","volume":"119","author":"Chugh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib72","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.8764","article-title":"First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review","volume":"12","author":"Arzivian","year":"2024","journal-title":"Clin Case Rep"},{"key":"10.1053\/j.gastro.2024.10.001_bib74","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.14309\/01.ajg.0000798724.11932.76","article-title":"P031 Impact of prior biologic exposure on response to ozanimod for moderate-to-severe ulcerative colitis in the phase 3 True North study","volume":"116","author":"Sands","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221074188","article-title":"Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland","volume":"15","author":"Perrig","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib76","first-page":"606","article-title":"Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the Eneida Registry","volume":"26","author":"Casanova","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.10.001_bib77","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/ecco-jcc\/jjad022","article-title":"Mercaptopurine for the treatment of ulcerative colitis: a randomized placebo-controlled trial","volume":"17","author":"Lowenberg","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.10.001_bib78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v5.i2.63","article-title":"Use of thiopurines in inflammatory bowel disease: safety issues","volume":"5","author":"Konidari","year":"2014","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/gutjnl-2019-320185","article-title":"Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource","volume":"70","author":"Stournaras","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.10.001_bib80","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib82","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.10.001_bib83","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib84","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1\u221705 Carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.10.001_bib85","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.cgh.2020.07.012","article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","volume":"19","author":"Hu","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cgh.2020.06.071","article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","volume":"19","author":"Yzet","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib87","doi-asserted-by":"crossref","unstructured":"Pudipeddi A, Paramsothy S, Kariyawasam V, et\u00a0al. Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial [published online ahead of print May 9, 2024]. Clin Gastroenterol Hepatol https:\/\/doi.org\/10.1016\/j.cgh.2024.04.019.","DOI":"10.1016\/j.cgh.2024.04.019"},{"key":"10.1053\/j.gastro.2024.10.001_bib88","first-page":"3142","article-title":"Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease","volume":"9","author":"Vaughn","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1053\/j.gastro.2024.10.001_bib89","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cgh.2021.01.002","article-title":"Therapeutic drug monitoring of non-anti-tumor necrosis factor biologics","volume":"19","author":"Shukla","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cgh.2023.08.039","article-title":"Withdrawal of immunomodulators or TNF antagonists in patients with inflammatory bowel diseases in remission on combination therapy: a systematic review and meta-analysis","volume":"22","author":"Katibian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib91","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2017.09.061","article-title":"Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission","volume":"16","author":"Reenaers","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib92","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/j.cgh.2022.01.019","article-title":"Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease","volume":"20","author":"Mahmoud","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib93","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.10.001_bib94","first-page":"79","article-title":"Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis","volume":"22","author":"Sood","year":"2003","journal-title":"Indian J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.10.001_bib96","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.10.001_bib97","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1572-0241.2004.11481.x","article-title":"A\u00a0prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis","volume":"99","author":"Mantzaris","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.10.001_bib98","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib99","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/gutjnl-2018-317021","article-title":"Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts","volume":"68","author":"Ungaro","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.10.001_bib100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/apt.15876","article-title":"No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy","volume":"52","author":"Singh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib101","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.18102","article-title":"Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: a nationwide population-based study","volume":"60","author":"Seo","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.10.001_bib102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000518865","article-title":"5-Aminosalicylic acid chemoprevention in inflammatory bowel diseases: is it necessary in the age of biologics and small molecules?","volume":"7","author":"Herfarth","year":"2022","journal-title":"Inflamm Intest Dis"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852405563X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852405563X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T09:47:46Z","timestamp":1732009666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852405563X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S001650852405563X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}